Kane Biotech Inc.
KNE.V
TSX
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 107.43% | 1,077.66% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 107.43% | 1,077.66% | |||
| Cost of Revenue | 179.37% | 2,059.09% | |||
| Gross Profit | 55.48% | 787.21% | |||
| SG&A Expenses | 1.17% | 22.53% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.27% | 36.94% | |||
| Operating Income | 44.39% | 8.53% | |||
| Income Before Tax | 44.01% | 19.79% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 44.01% | 19.79% | |||
| Earnings from Discontinued Operations | -99.30% | 10,352.82% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -106.62% | 748.18% | |||
| EBIT | 44.39% | 8.53% | |||
| EBITDA | 45.95% | 11.29% | |||
| EPS Basic | -106.51% | 741.77% | |||
| Normalized Basic EPS | 45.24% | 20.75% | |||
| EPS Diluted | -116.91% | 616.46% | |||
| Normalized Diluted EPS | 34.29% | 33.96% | |||
| Average Basic Shares Outstanding | 1.08% | 0.39% | |||
| Average Diluted Shares Outstanding | -15.33% | 19.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
